BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:360-368. [PMID: 26026936 DOI: 10.1016/s0140-6736(15)60860-1] [Cited by in Crossref: 254] [Cited by in F6Publishing: 116] [Article Influence: 42.3] [Reference Citation Analysis]
Number Citing Articles
1 Magallón M, Carrión AE, Bañuls L, Pellicer D, Castillo S, Bondía S, Navarro-García MM, González C, Dasí F. Oxidative Stress and Endoplasmic Reticulum Stress in Rare Respiratory Diseases. J Clin Med 2021;10:1268. [PMID: 33803835 DOI: 10.3390/jcm10061268] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Dolliver WR, Diaz AA. Advances in Chronic Obstructive Pulmonary Disease Imaging. Barc Respir Netw Rev 2020;6:128-43. [PMID: 33758787 DOI: 10.23866/brnrev:2019-0023] [Reference Citation Analysis]
3 Paul-Smith MC, Pytel KM, Gelinas JF, McIntosh J, Pringle I, Davies L, Chan M, Meng C, Bell R, Cammack L, Moran C, Cameron L, Inoue M, Tsugumine S, Hironaka T, Gill DR, Hyde SC, Nathwani A, Alton EWFW, Griesenbach U. The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins. Gene Ther 2018;25:345-58. [PMID: 30022127 DOI: 10.1038/s41434-018-0025-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
4 Zarei S, Mirtar A, Morrow JD, Castaldi PJ, Belloni P, Hersh CP. Subtyping Chronic Obstructive Pulmonary Disease Using Peripheral Blood Proteomics. Chronic Obstr Pulm Dis 2017;4:97-108. [PMID: 28848918 DOI: 10.15326/jcopdf.4.2.2016.0147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Gramegna A, Amati F, Terranova L, Sotgiu G, Tarsia P, Miglietta D, Calderazzo MA, Aliberti S, Blasi F. Neutrophil elastase in bronchiectasis. Respir Res 2017;18:211. [PMID: 29258516 DOI: 10.1186/s12931-017-0691-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
6 Karl FM, Holle R, Bals R, Greulich T, Jörres RA, Karch A, Koch A, Karrasch S, Leidl R, Schulz H, Vogelmeier C, Wacker ME; COSYCONET Study Group. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respir Res 2017;18:60. [PMID: 28416015 DOI: 10.1186/s12931-017-0543-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
7 Campos MA, Runken MC, Davis AM, Johnson MP, Stone GA, Buikema AR. Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis. Adv Ther 2018;35:467-81. [PMID: 29616482 DOI: 10.1007/s12325-018-0690-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Parr DG, Lara B. Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature. Drug Des Devel Ther 2017;11:2149-62. [PMID: 28769553 DOI: 10.2147/DDDT.S105207] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 Horváth I, Canotilho M, Chlumský J, Chorostowska-Wynimko J, Corda L, Derom E, Ficker JH, Kneussl M, Miravitlles M, Sucena M, Thabut G, Turner AM, van 't Wout E, McElvaney NG. Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res 2019;5:00171-2018. [PMID: 30863774 DOI: 10.1183/23120541.00171-2018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
10 Kueppers F, Andrake MD, Xu Q, Dunbrack RL Jr, Kim J, Sanders CL. Protein modeling to assess the pathogenicity of rare variants of SERPINA1 in patients suspected of having Alpha 1 Antitrypsin Deficiency. BMC Med Genet 2019;20:125. [PMID: 31307431 DOI: 10.1186/s12881-019-0852-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Yang C, Keshavjee S, Liu M. Alpha-1 Antitrypsin for COVID-19 Treatment: Dual Role in Antiviral Infection and Anti-Inflammation. Front Pharmacol 2020;11:615398. [PMID: 33362565 DOI: 10.3389/fphar.2020.615398] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
12 Attaway A, Majumdar U, Sandhaus RA, Nowacki AS, Stoller JK. An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2019;14:2089-101. [PMID: 31564856 DOI: 10.2147/COPD.S208591] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
13 Franciosi AN, Hobbs BD, McElvaney OJ, Molloy K, Hersh C, Clarke L, Gunaratnam C, Silverman EK, Carroll TP, McElvaney NG. Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2020;202:73-82. [PMID: 32197047 DOI: 10.1164/rccm.202002-0262OC] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 10.0] [Reference Citation Analysis]
14 Ostermann L, Maus R, Stolper J, Schütte L, Katsarou K, Tumpara S, Pich A, Mueller C, Janciauskiene S, Welte T, Maus UA. Alpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice. JCI Insight 2021;6:140816. [PMID: 33554955 DOI: 10.1172/jci.insight.140816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Stockley JA, Stockley RA, Sapey E. There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements. Int J Chron Obstruct Pulmon Dis 2021;16:835-40. [PMID: 33824583 DOI: 10.2147/COPD.S298585] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Balbi B, Sangiorgi C, Gnemmi I, Ferrarotti I, Vallese D, Paracchini E, Delle Donne L, Corda L, Baderna P, Corsico A, Carone M, Brun P, Cappello F, Ricciardolo FL, Ruggeri P, Mumby S, Adcock IM, Caramori G, Di Stefano A. Bacterial load and inflammatory response in sputum of alpha-1 antitrypsin deficiency patients with COPD. Int J Chron Obstruct Pulmon Dis 2019;14:1879-93. [PMID: 31686800 DOI: 10.2147/COPD.S207203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Belchamber KBR, Hughes MJ, Spittle DA, Walker EM, Sapey E. New Pharmacological Tools to Target Leukocyte Trafficking in Lung Disease. Front Immunol 2021;12:704173. [PMID: 34367163 DOI: 10.3389/fimmu.2021.704173] [Reference Citation Analysis]
18 Chorostowska-Wynimko J, Barrecheguren M, Ferrarotti I, Greulich T, Sandhaus RA, Campos M. New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency. Int J Chron Obstruct Pulmon Dis 2020;15:345-55. [PMID: 32103933 DOI: 10.2147/COPD.S234646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
19 Hersh CP. Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicine. F1000Res 2017;6:2049. [PMID: 29225784 DOI: 10.12688/f1000research.12399.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Come CE, Washko GR. CT Scanning in COPD - Is it Time to Move On? Chronic Obstr Pulm Dis 2015;2:201-3. [PMID: 28848843 DOI: 10.15326/jcopdf.2.3.2015.0150] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Hassan T, de Santi C, Mooney C, McElvaney NG, Greene CM. Alpha-1 antitrypsin augmentation therapy decreases miR-199a-5p, miR-598 and miR-320a expression in monocytes via inhibition of NFκB. Sci Rep 2017;7:13803. [PMID: 29062067 DOI: 10.1038/s41598-017-14310-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Bodduluri S, Reinhardt JM, Hoffman EA, Newell JD Jr, Bhatt SP. Recent Advances in Computed Tomography Imaging in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2018;15:281-9. [PMID: 28812906 DOI: 10.1513/AnnalsATS.201705-377FR] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
23 Nakanishi T, Forgetta V, Handa T, Hirai T, Mooser V, Lathrop GM, Cookson WOCM, Richards JB. The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes. Eur Respir J 2020;56:2001441. [PMID: 32675199 DOI: 10.1183/13993003.01441-2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
24 Sosulski ML, Stiles KM, Frenk EZ, Hart FM, Matsumura Y, De BP, Kaminsky SM, Crystal RG. Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin. JCI Insight 2020;5:135951. [PMID: 32759494 DOI: 10.1172/jci.insight.135951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Tortorici MA, Rogers JA, Vit O, Bexon M, Sandhaus RA, Burdon J, Chorostowska-Wynimko J, Thompson P, Stocks J, McElvaney NG, Chapman KR, Edelman JM. Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency. Br J Clin Pharmacol 2017;83:2386-97. [PMID: 28662542 DOI: 10.1111/bcp.13358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
26 Borel F, Tang Q, Gernoux G, Greer C, Wang Z, Barzel A, Kay MA, Shultz LD, Greiner DL, Flotte TR, Brehm MA, Mueller C. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency. Mol Ther 2017;25:2477-89. [PMID: 29032169 DOI: 10.1016/j.ymthe.2017.09.020] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 8.8] [Reference Citation Analysis]
27 Sandhaus RA, Turino G, Brantly ML, Campos M, Cross CE, Goodman K, Hogarth DK, Knight SL, Stocks JM, Stoller JK, Strange C, Teckman J. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obstr Pulm Dis 2016;3:668-82. [PMID: 28848891 DOI: 10.15326/jcopdf.3.3.2015.0182] [Cited by in Crossref: 40] [Cited by in F6Publishing: 51] [Article Influence: 8.0] [Reference Citation Analysis]
28 Newby PR, Crossley D, Crisford H, Stockley JA, Mumford RA, Carter RI, Bolton CE, Hopkinson NS, Mahadeva R, Steiner MC, Wilkinson TMA, Sapey E, Stockley RA. A specific proteinase 3 activity footprint in α1-antitrypsin deficiency. ERJ Open Res 2019;5:00095-2019. [PMID: 31403052 DOI: 10.1183/23120541.00095-2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Song CQ, Wang D, Jiang T, O'Connor K, Tang Q, Cai L, Li X, Weng Z, Yin H, Gao G, Mueller C, Flotte TR, Xue W. In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. Hum Gene Ther 2018;29:853-60. [PMID: 29597895 DOI: 10.1089/hum.2017.225] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
30 Campos MA, Geraghty P, Holt G, Mendes E, Newby PR, Ma S, Luna-Diaz LV, Turino GM, Stockley RA. The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial. Am J Respir Crit Care Med 2019;200:318-26. [PMID: 30965011 DOI: 10.1164/rccm.201901-0010OC] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 29.0] [Reference Citation Analysis]
31 Deuse T, Tediashvili G, Hu X, Gravina A, Tamenang A, Wang D, Connolly A, Mueller C, Mallavia B, Looney MR, Alawi M, Lanier LL, Schrepfer S. Hypoimmune induced pluripotent stem cell-derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice. Proc Natl Acad Sci U S A 2021;118:e2022091118. [PMID: 34244428 DOI: 10.1073/pnas.2022091118] [Reference Citation Analysis]
32 O'Brien ME, Fee L, Browne N, Carroll TP, Meleady P, Henry M, McQuillan K, Murphy MP, Logan M, McCarthy C, McElvaney OJ, Reeves EP, McElvaney NG. Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency. Thorax 2020;75:321-30. [PMID: 31959730 DOI: 10.1136/thoraxjnl-2019-214076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
33 Stockley RA. Alpha-1 Antitrypsin Deficiency: Have We Got the Right Proteinase? Chronic Obstr Pulm Dis 2020;7:163-71. [PMID: 32396717 DOI: 10.15326/jcopdf.7.3.2019.0151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Viglio S, Bak EG, Schouten IGM, Iadarola P, Stolk J. Protease-Specific Biomarkers to Analyse Protease Inhibitors for Emphysema Associated with Alpha 1-Antitrypsin Deficiency. An Overview of Current Approaches. Int J Mol Sci 2021;22:1065. [PMID: 33494436 DOI: 10.3390/ijms22031065] [Reference Citation Analysis]
35 Ferrarotti I, Ottaviani S, De Silvestri A, Corsico AG. Update on α1-antitrypsin deficiency. Breathe (Sheff) 2018;14:e17-24. [PMID: 30131830 DOI: 10.1183/20734735.015018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
36 Kueppers F. Clinical presentations of four patients with rare Alpha 1 Antitrypsin variants identified in a single US center. Respir Med Case Rep 2021;32:101345. [PMID: 33552892 DOI: 10.1016/j.rmcr.2021.101345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Diaz AA, Strand M, Coxson HO, Ross JC, San Jose Estepar R, Lynch D, van Rikxoort EM, Rosas IO, Hunninghake GM, Putman RK, Hatabu H, Yen A, Kinney GL, Hokanson JE, Silverman EK, Crapo J, Washko GR. Disease Severity Dependence of the Longitudinal Association Between CT Lung Density and Lung Function in Smokers. Chest 2018;153:638-45. [PMID: 29066389 DOI: 10.1016/j.chest.2017.10.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
38 Moxey JM, Low EV, Turner AM. Rare case of eosinophilic granulomatosis with polyangiitis in two patients with α-1-antitrypsin deficiency (PiSZ). BMJ Case Rep 2016;2016:bcr2015214118. [PMID: 27118743 DOI: 10.1136/bcr-2015-214118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
39 Silverman EK. Genetics of COPD. Annu Rev Physiol 2020;82:413-31. [PMID: 31730394 DOI: 10.1146/annurev-physiol-021317-121224] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
40 Ma S, Geraghty P, Dabo A, McCarthy C, McElvaney NG, Turino GM. Cystic fibrosis disease severity correlates with plasma levels of desmosine and isodesmosine, biomarkers of elastin degradation. ERJ Open Res 2019;5:00250-2018. [PMID: 31218219 DOI: 10.1183/23120541.00250-2018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Lorincz R, Curiel DT. Advances in Alpha-1 Antitrypsin Gene Therapy. Am J Respir Cell Mol Biol 2020;63:560-70. [PMID: 32668173 DOI: 10.1165/rcmb.2020-0159PS] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
42 Schouten IGM, Mumford RA, Moes DJAR, Hiemstra PS, Stolk J. The Course of AαVal541 as a Proteinase 3 Specific Neo-Epitope after Alpha-1-Antitrypsin Augmentation in Severe Deficient Patients. Int J Mol Sci 2021;22:8031. [PMID: 34360796 DOI: 10.3390/ijms22158031] [Reference Citation Analysis]
43 Chiuchiolo MJ, Crystal RG. Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease. Ann Am Thorac Soc 2016;13 Suppl 4:S352-69. [PMID: 27564673 DOI: 10.1513/AnnalsATS.201506-344KV] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
44 Greulich T, Chlumsky J, Wencker M, Vit O, Fries M, Chung T, Shebl A, Vogelmeier C, Chapman KR, McElvaney NG; RAPID Trial Group. Safety of biweekly α1-antitrypsin treatment in the RAPID programme. Eur Respir J 2018;52:1800897. [PMID: 30237305 DOI: 10.1183/13993003.00897-2018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 Perkins JT, Choate R, Mannino DM, Browning SR, Sandhaus RA. Benefits Among Patients with Alpha-1 Antitrypsin Deficiency Enrolled in a Disease Management and Prevention Program. Chronic Obstr Pulm Dis 2016;4:56-64. [PMID: 28848911 DOI: 10.15326/jcopdf.4.1.2016.0161] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
46 Sidhaye VK, Nishida K, Martinez FJ. Precision medicine in COPD: where are we and where do we need to go? Eur Respir Rev 2018;27:180022. [PMID: 30068688 DOI: 10.1183/16000617.0022-2018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 9.7] [Reference Citation Analysis]
47 McKelvey MC, Weldon S, McAuley DF, Mall MA, Taggart CC. Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential. Am J Respir Crit Care Med 2020;201:141-7. [PMID: 31626562 DOI: 10.1164/rccm.201906-1190PP] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 21.0] [Reference Citation Analysis]
48 McElvaney OF, Murphy MP, Reeves EP, McElvaney NG. Anti-cytokines as a Strategy in Alpha-1 Antitrypsin Deficiency. Chronic Obstr Pulm Dis 2020;7:203-13. [PMID: 32503090 DOI: 10.15326/jcopdf.7.3.2019.0171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Podolanczuk AJ, Oelsner EC, Barr RG, Hoffman EA, Armstrong HF, Austin JH, Basner RC, Bartels MN, Christie JD, Enright PL, Gochuico BR, Hinckley Stukovsky K, Kaufman JD, Hrudaya Nath P, Newell JD Jr, Palmer SM, Rabinowitz D, Raghu G, Sell JL, Sieren J, Sonavane SK, Tracy RP, Watts JR, Williams K, Kawut SM, Lederer DJ. High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. Eur Respir J 2016;48:1442-52. [PMID: 27471206 DOI: 10.1183/13993003.00129-2016] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 14.0] [Reference Citation Analysis]
50 Kirby M, Hatt C, Obuchowski N, Humphries SM, Sieren J, Lynch DA, Fain SB; QIBA Lung Density Committee. Inter- and intra-software reproducibility of computed tomography lung density measurements. Med Phys 2020;47:2962-9. [PMID: 32160310 DOI: 10.1002/mp.14130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
51 Sandhaus RA, Strange C, Zanichelli A, Skålvoll K, Koczulla AR, Stockley RA. Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency. Int J Chron Obstruct Pulmon Dis 2020;15:3313-22. [PMID: 33328731 DOI: 10.2147/COPD.S276773] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Beiko T, Janech MG, Alekseyenko AV, Atkinson C, Coxson HO, Barth JL, Stephenson SE, Wilson CL, Schnapp LM, Barker A, Brantly M, Sandhaus RA, Silverman EK, Stoller JK, Trapnell B, Charlie S. Serum Proteins Associated with Emphysema Progression in Severe Alpha-1 Antitrypsin Deficiency. Chronic Obstr Pulm Dis 2017;4:204-16. [PMID: 28848932 DOI: 10.15326/jcopdf.4.3.2016.0180] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Strange C, Senior RM, Sciurba F, O'Neal S, Morris A, Wisniewski SR, Bowler R, Hochheiser HS, Becich MJ, Zhang Y, Leader JK, Methé BA, Kaminski N, Sandhaus RA; GRADS Alpha-1 Study Group. Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol. Ann Am Thorac Soc 2015;12:1551-60. [PMID: 26153726 DOI: 10.1513/AnnalsATS.201503-143OC] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
54 Brantly ML, Lascano JE, Shahmohammadi A. Intravenous Alpha-1 Antitrypsin Therapy for Alpha-1 Antitrypsin Deficiency: The Current State of the Evidence. Chronic Obstr Pulm Dis 2018;6:100-14. [PMID: 30775428 DOI: 10.15326/jcopdf.6.1.2017.0185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
55 McKelvey MC, Brown R, Ryan S, Mall MA, Weldon S, Taggart CC. Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease. Int J Mol Sci 2021;22:5018. [PMID: 34065111 DOI: 10.3390/ijms22095018] [Reference Citation Analysis]
56 Chorostowska-Wynimko J, Wencker M, Horváth I. The importance of effective registries in pulmonary diseases and how to optimize their output. Chron Respir Dis 2019;16:1479973119881777. [PMID: 31645111 DOI: 10.1177/1479973119881777] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
57 Esquinas C, Serreri S, Barrecheguren M, Rodriguez E, Nuñez A, Casas-Maldonado F, Blanco I, Pirina P, Lara B, Miravitlles M. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT). Int J Chron Obstruct Pulmon Dis 2018;13:1001-7. [PMID: 29615836 DOI: 10.2147/COPD.S155226] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
58 Krotova K, Marek GW, Wang RL, Aslanidi G, Hoffman BE, Khodayari N, Rouhani FN, Brantly ML. Alpha-1 Antitrypsin-Deficient Macrophages Have Increased Matriptase-Mediated Proteolytic Activity. Am J Respir Cell Mol Biol 2017;57:238-47. [PMID: 28362108 DOI: 10.1165/rcmb.2016-0366OC] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
59 Stockley RA, Edgar RG, Starkey S, Turner AM. Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies? Respir Res 2018;19:137. [PMID: 30029692 DOI: 10.1186/s12931-018-0844-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
60 Hersh CP, Campbell EJ, Scott LR, Raby BA. Alpha-1 Antitrypsin Deficiency as an Incidental Finding in Clinical Genetic Testing. Am J Respir Crit Care Med 2019;199:246-8. [PMID: 30359090 DOI: 10.1164/rccm.201809-1679LE] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
61 Stockley RA, Edgar RG, Pillai A, Turner AM. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management? Int J Chron Obstruct Pulmon Dis 2016;11:1745-56. [PMID: 27536086 DOI: 10.2147/COPD.S111508] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 4.4] [Reference Citation Analysis]
62 Rahaghi FF, Miravitlles M. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence. Respir Res 2017;18:105. [PMID: 28558837 DOI: 10.1186/s12931-017-0574-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
63 Parikh MA, Aaron CP, Hoffman EA, Schwartz JE, Madrigano J, Austin JHM, Kalhan R, Lovasi G, Watson K, Stukovsky KH, Barr RG. Angiotensin-Converting Inhibitors and Angiotensin II Receptor Blockers and Longitudinal Change in Percent Emphysema on Computed Tomography. The Multi-Ethnic Study of Atherosclerosis Lung Study. Ann Am Thorac Soc 2017;14:649-58. [PMID: 28207279 DOI: 10.1513/AnnalsATS.201604-317OC] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
64 Baranovski BM, Schuster R, Nisim O, Brami I, Lior Y, Lewis EC. Alpha-1 Antitrypsin Substitution for Extrapulmonary Conditions in Alpha-1 Antitrypsin Deficient Patients. Chronic Obstr Pulm Dis 2018;5:267-76. [PMID: 30723784 DOI: 10.15326/jcopdf.5.4.2017.0161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
65 Lomas DA. New Therapeutic Targets for Alpha-1 Antitrypsin Deficiency. Chronic Obstr Pulm Dis 2018;5:233-43. [PMID: 30723781 DOI: 10.15326/jcopdf.5.4.2017.0165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
66 Chapman KR. Bench to Bedside and Back: The Evolving Story of Alpha-1 Antitrypsin Deficiency. Am J Respir Cell Mol Biol 2020;63:403-4. [PMID: 32716630 DOI: 10.1165/rcmb.2020-0243ED] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Martini F, De Mattei M, Contini C, Tognon MG. Potential Use of Alpha-1 Anti-trypsin in the Covid-19 Treatment. Front Cell Dev Biol 2020;8:577528. [PMID: 33195215 DOI: 10.3389/fcell.2020.577528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
68 Campos MA, Diaz AA. The Role of Computed Tomography for the Evaluation of Lung Disease in Alpha-1 Antitrypsin Deficiency. Chest 2018;153:1240-8. [PMID: 29175361 DOI: 10.1016/j.chest.2017.11.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
69 Janosz E, Hetzel M, Spielmann H, Tumpara S, Rossdam C, Schwabbauer M, Kloos D, von Kaisenberg C, Schambach A, Buettner FFR, Janciauskiene S, Lachmann N, Moritz T. Pulmonary transplantation of alpha-1 antitrypsin (AAT)-transgenic macrophages provides a source of functional human AAT in vivo. Gene Ther 2021. [PMID: 34276045 DOI: 10.1038/s41434-021-00269-3] [Reference Citation Analysis]
70 Labaki WW, Martinez CH, Martinez FJ, Galbán CJ, Ross BD, Washko GR, Barr RG, Regan EA, Coxson HO, Hoffman EA, Newell JD Jr, Curran-Everett D, Hogg JC, Crapo JD, Lynch DA, Kazerooni EA, Han MK. The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2017;196:1372-9. [PMID: 28661698 DOI: 10.1164/rccm.201703-0451PP] [Cited by in Crossref: 53] [Cited by in F6Publishing: 24] [Article Influence: 13.3] [Reference Citation Analysis]
71 Stockley JA, Cooper BG, Stockley RA, Sapey E. Small airways disease: time for a revisit? Int J Chron Obstruct Pulmon Dis 2017;12:2343-53. [PMID: 28848335 DOI: 10.2147/COPD.S138540] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
72 Crapo J, Gupta A, Lynch DA, Vogel-Claussen J, Watz H, Turner AM, Mroz RM, Janssens W, Ludwig-Sengpiel A, Beck M, Langellier B, Ittrich C, Risse F, Diefenbach C. FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD. BMJ Open 2021;11:e042526. [PMID: 33753437 DOI: 10.1136/bmjopen-2020-042526] [Reference Citation Analysis]
73 Myc LA, Shim YM, Laubach VE, Dimastromatteo J. Role of medical and molecular imaging in COPD. Clin Transl Med 2019;8:12. [PMID: 30989390 DOI: 10.1186/s40169-019-0231-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
74 Annunziata A, Lanza M, Coppola A, Andreozzi P, Spinelli S, Fiorentino G. Alpha-1 Antitrypsin Deficiency: Home Therapy. Front Pharmacol 2021;12:575402. [PMID: 33935692 DOI: 10.3389/fphar.2021.575402] [Reference Citation Analysis]
75 Spineli LM, Jenz E, Großhennig A, Koch A. Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease. Orphanet J Rare Dis 2017;12:140. [PMID: 28814322 DOI: 10.1186/s13023-017-0692-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
76 Gøtzsche PC, Johansen HK; Cochrane Airways Group. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd007851.pub3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
77 Barrecheguren M, O'Hara K, Wilkens M, Boyd J, Kolda E, Lara B, Chorostowska-Wynimko J, Ferrarotti I, Chlumský J, Clarenbach C, Greulich T, Miravitlles M, Sucena M. Research priorities in α1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration. ERJ Open Res 2020;6:00523-2020. [PMID: 33447613 DOI: 10.1183/23120541.00523-2020] [Reference Citation Analysis]
78 Torres-Durán M, Lopez-Campos JL, Barrecheguren M, Miravitlles M, Martinez-Delgado B, Castillo S, Escribano A, Baloira A, Navarro-Garcia MM, Pellicer D, Bañuls L, Magallón M, Casas F, Dasí F. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis 2018;13:114. [PMID: 29996870 DOI: 10.1186/s13023-018-0856-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 15.7] [Reference Citation Analysis]
79 Sahu I, Haque AKMA, Weidensee B, Weinmann P, Kormann MSD. Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases. Mol Ther 2019;27:803-23. [PMID: 30905577 DOI: 10.1016/j.ymthe.2019.02.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
80 Wozniak J, Wandtke T, Kopinski P, Chorostowska-Wynimko J. Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy. Hum Gene Ther 2015;26:709-18. [PMID: 26413996 DOI: 10.1089/hum.2015.044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
81 Takeda K, Kim SH, Joetham A, Petrache I, Gelfand EW. Therapeutic benefits of recombinant alpha1-antitrypsin IgG1 Fc-fusion protein in experimental emphysema. Respir Res 2021;22:207. [PMID: 34271910 DOI: 10.1186/s12931-021-01784-y] [Reference Citation Analysis]
82 Kerstjens HAM, Upham JW, Yang IA. Airway pharmacology: treatment options and algorithms to treat patients with chronic obstructive pulmonary disease. J Thorac Dis 2019;11:S2200-9. [PMID: 31737347 DOI: 10.21037/jtd.2019.10.57] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
83 Segal LN, Martinez FJ. Chronic obstructive pulmonary disease subpopulations and phenotyping. J Allergy Clin Immunol 2018;141:1961-71. [PMID: 29884286 DOI: 10.1016/j.jaci.2018.02.035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
84 Dunlea DM, Fee LT, McEnery T, McElvaney NG, Reeves EP. The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals. J Inflamm Res 2018;11:123-34. [PMID: 29618937 DOI: 10.2147/JIR.S156405] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
85 Wang F, Orioli S, Ianeselli A, Spagnolli G, A Beccara S, Gershenson A, Faccioli P, Wintrode PL. All-Atom Simulations Reveal How Single-Point Mutations Promote Serpin Misfolding. Biophys J 2018;114:2083-94. [PMID: 29742402 DOI: 10.1016/j.bpj.2018.03.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
86 Craig TJ, Henao MP. Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder. Allergy 2018;73:2110-21. [PMID: 29984428 DOI: 10.1111/all.13558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
87 Spratt JR, Brown RZ, Rudser K, Goswami U, Hertz MI, Patil J, Cich I, Shumway SJ, Loor G. Greater survival despite increased complication rates following lung transplant for alpha-1-antitrypsin deficiency compared to chronic obstructive pulmonary disease. J Thorac Dis 2019;11:1130-44. [PMID: 31179055 DOI: 10.21037/jtd.2019.04.40] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
88 Park SS, Rodriguez Ortega R, Agudelo CW, Perez Perez J, Perez Gandara B, Garcia-Arcos I, McCarthy C, Geraghty P. Therapeutic Potential of Alpha-1 Antitrypsin in Type 1 and Type 2 Diabetes Mellitus. Medicina (Kaunas) 2021;57:397. [PMID: 33923873 DOI: 10.3390/medicina57040397] [Reference Citation Analysis]
89 Ma S, Lin YY, Cantor JO, Chapman KR, Sandhaus RA, Fries M, Edelman JM, McElvaney G, Turino GM. The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials. Chronic Obstr Pulm Dis 2016;4:34-44. [PMID: 28848909 DOI: 10.15326/jcopdf.4.1.2016.0156] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
90 McElvaney GN, Sandhaus RA, Miravitlles M, Turino GM, Seersholm N, Wencker M, Stockley RA. Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype. Eur Respir J 2020;55:1902410. [PMID: 32165400 DOI: 10.1183/13993003.02410-2019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
91 Celli BR, Agustí A. COPD: time to improve its taxonomy? ERJ Open Res 2018;4:00132-2017. [PMID: 29707563 DOI: 10.1183/23120541.00132-2017] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 12.7] [Reference Citation Analysis]
92 Wanner A. Towards New Therapeutic Solutions for Alpha-1 Antitrypsin Deficiency: Role of the Alpha-1 Foundation. Chronic Obstr Pulm Dis 2020;7:147-50. [PMID: 32726072 DOI: 10.15326/jcopdf.7.3.2020.0141] [Reference Citation Analysis]
93 Kahnert K, Jobst B, Biertz F, Biederer J, Watz H, Huber RM, Behr J, Grenier PA, Alter P, Vogelmeier CF, Kauczor HU, Jörres RA. Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans. Chron Respir Dis 2019;16:1479972318775423. [PMID: 29742906 DOI: 10.1177/1479972318775423] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
94 Silberstein DZ, Karuppanan K, Aung HH, Chen CH, Cross CE, McDonald KA. An oxidation-resistant, recombinant alpha-1 antitrypsin produced in Nicotiana benthamiana. Free Radic Biol Med 2018;120:303-10. [PMID: 29551638 DOI: 10.1016/j.freeradbiomed.2018.03.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
95 Agustí A, Celli B. Natural history of COPD: gaps and opportunities. ERJ Open Res 2017;3:00117-2017. [PMID: 29255718 DOI: 10.1183/23120541.00117-2017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
96 Stoel BC, Stolk J, Bakker ME, Parr DG. Regional lung densities in alpha-1 antitrypsin deficiency compared to predicted values. Respir Res 2019;20:45. [PMID: 30819163 DOI: 10.1186/s12931-019-1012-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Schuster R, Bar-Nathan O, Tiosano A, Lewis EC, Silberstein E. Enhanced Survival and Accelerated Perfusion of Skin Flap to Recipient Site Following Administration of Human α1-Antitrypsin in Murine Models. Adv Wound Care (New Rochelle) 2019;8:281-90. [PMID: 31737418 DOI: 10.1089/wound.2018.0889] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
98 Edgar RG, Patel M, Bayliss S, Crossley D, Sapey E, Turner AM. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. Int J Chron Obstruct Pulmon Dis 2017;12:1295-308. [PMID: 28496314 DOI: 10.2147/COPD.S130440] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 8.3] [Reference Citation Analysis]
99 Sala V, Murabito A, Ghigo A. Inhaled Biologicals for the Treatment of Cystic Fibrosis. Recent Pat Inflamm Allergy Drug Discov 2019;13:19-26. [PMID: 30318010 DOI: 10.2174/1872213X12666181012101444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
100 Reeves EP, Dunlea DM, McQuillan K, O'Dwyer CA, Carroll TP, Saldova R, Akepati PR, Wormald MR, McElvaney OJ, Shutchaidat V, Henry M, Meleady P, Keenan J, Liberti DC, Kotton DN, Rudd PM, Wilson AA, McElvaney NG. Circulating Truncated Alpha-1 Antitrypsin Glycoprotein in Patient Plasma Retains Anti-Inflammatory Capacity. J Immunol 2019;202:2240-53. [PMID: 30796179 DOI: 10.4049/jimmunol.1801045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
101 Foil KE, Blanton MG, Sanders C, Kim J, Al Ashry HS, Kumbhare S, Strange C. Sequencing Alpha-1 MZ Individuals Shows Frequent Biallelic Mutations. Pulm Med 2018;2018:2836389. [PMID: 30254761 DOI: 10.1155/2018/2836389] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
102 Gramegna A, Aliberti S, Confalonieri M, Corsico A, Richeldi L, Vancheri C, Blasi F. Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. Multidiscip Respir Med 2018;13:39. [PMID: 30338069 DOI: 10.1186/s40248-018-0153-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
103 Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, Clarenbach C, Corda L, Corsico AG, Ferrarotti I, Esquinas C, Gouder C, Hećimović A, Ilic A, Ivanov Y, Janciauskiene S, Janssens W, Kohler M, Krams A, Lara B, Mahadeva R, McElvaney G, Mornex JF, O'Hara K, Parr D, Piitulainen E, Schmid-Scherzer K, Seersholm N, Stockley RA, Stolk J, Sucena M, Tanash H, Turner A, Ulmeanu R, Wilkens M, Yorgancioğlu A, Zaharie A, Miravitlles M. Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency. ERJ Open Res 2020;6:00181-2019. [PMID: 32154291 DOI: 10.1183/23120541.00181-2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
104 González G, Washko GR, Estépar RSJ. Deep learning for biomarker regression: application to osteoporosis and emphysema on chest CT scans. Proc SPIE Int Soc Opt Eng 2018;10574:105741H. [PMID: 30122802 DOI: 10.1117/12.2293455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
105 Chapman KR, Chorostowska-Wynimko J, Koczulla AR, Ferrarotti I, McElvaney NG. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications. Int J Chron Obstruct Pulmon Dis 2018;13:419-32. [PMID: 29430176 DOI: 10.2147/COPD.S149429] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 6.7] [Reference Citation Analysis]
106 Stiles KM, Sondhi D, Kaminsky SM, De BP, Rosenberg JB, Crystal RG. Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease. Chronic Obstr Pulm Dis 2018;5:244-57. [PMID: 30723782 DOI: 10.15326/jcopdf.5.4.2017.0160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
107 Hersh CP. Pharmacogenomics of chronic obstructive pulmonary disease. Expert Rev Respir Med 2019;13:459-70. [PMID: 30925849 DOI: 10.1080/17476348.2019.1601559] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
108 Wilkinson DJ. Serpins in cartilage and osteoarthritis: what do we know? Biochem Soc Trans 2021;49:1013-26. [PMID: 33843993 DOI: 10.1042/BST20201231] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Brantly M, Campos M, Davis AM, D'Armiento J, Goodman K, Hanna K, O'Day M, Queenan J, Sandhaus R, Stoller J, Strange C, Teckman J, Wanner A. Detection of alpha-1 antitrypsin deficiency: the past, present and future. Orphanet J Rare Dis 2020;15:96. [PMID: 32306990 DOI: 10.1186/s13023-020-01352-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
110 López-Campos JL, Carrasco Hernandez L, Caballero Eraso C. Implications of a Change of Paradigm in Alpha1 Antitrypsin Deficiency Augmentation Therapy: From Biochemical to Clinical Efficacy. J Clin Med 2020;9:E2526. [PMID: 32764414 DOI: 10.3390/jcm9082526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Kim W, Cho MH, Sakornsakolpat P, Lynch DA, Coxson HO, Tal-Singer R, Silverman EK, Beaty TH. DSP variants may be associated with longitudinal change in quantitative emphysema. Respir Res 2019;20:160. [PMID: 31324189 DOI: 10.1186/s12931-019-1097-8] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
112 Máiz Carro L, Martínez-García MA. Use of Hyaluronic Acid (HA) in Chronic Airway Diseases. Cells 2020;9:E2210. [PMID: 33003557 DOI: 10.3390/cells9102210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
113 Crossley D, Renton M, Khan M, Low EV, Turner AM. CT densitometry in emphysema: a systematic review of its clinical utility. Int J Chron Obstruct Pulmon Dis 2018;13:547-63. [PMID: 29445272 DOI: 10.2147/COPD.S143066] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
114 Crossley D, Stockley R, Sapey E. Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease? Drugs Aging 2019;36:823-40. [PMID: 31179525 DOI: 10.1007/s40266-019-00684-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
115 Greulich T, Vogelmeier CF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis 2016;10:72-84. [PMID: 26341117 DOI: 10.1177/1753465815602162] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
116 Reeves EP, O'Dwyer CA, Dunlea DM, Wormald MR, Hawkins P, Alfares M, Kotton DN, Rowe SM, Wilson AA, McElvaney NG. Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations. Am J Respir Crit Care Med 2018;198:1099-102. [PMID: 30011228 DOI: 10.1164/rccm.201802-0338LE] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]